The urgency for effective diabetes and obesity treatments has never been more pronounced. According to the World Health Organization, the global prevalence of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% of the adult population. This surge underscores the critical need for innovative therapeutic options. Eli Lilly's (LLY) response to this demand has been not only timely but also highly successful, with its market-leading drug Mounjaro (tirzepatide) generating over $5 billion in sales in its first full year on the market — a testament to its efficacy and market demand.
Incretins like Mounjaro now account for a remarkable 27% of all diabetes prescriptions in the U.S., highlighting the rapid shift in treatment paradigms. Strong demand for GLP-1 drugs just inspired Eli Lilly to revise its 2024 revenue forecast upward by a staggering $2 billion, with the pharma giant now anticipating revenues to be between $42.4 billion and $43.6 billion - and the company just released more upbeat drug data, too.
